Cambridge Science Park, Unit 23
Exonate Limited was founded in 2013 and is based in Nottingham and Cambridge in the UK. Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis), which is a key driver of disease progression in ophthalmic conditions and cancer Exonate’s founders have identified and generated a novel class of drugs, “SPHINXes,” that modulate alternative mRNA splicing. We have developed a pipeline of molecules that promise therapeutics for anti-angiogenic therapies in ophthalmology, oncology, analgesia, diabetes, neurodegeneration and renal disease.
CEO: Dr. Catherine Beech MB ChB OBE
CSO: Professor David Bates
Medical Director: Professor Steven J. Harper
Founding Scientist: Dr. Lucy Donaldson
Please click here for Exonate's job opportunities.
Please click here for Exonate's technology.